S&P 500   3,978.47 (-2.70%)
DOW   31,899.16 (-2.31%)
QQQ   296.67 (-3.10%)
AAPL   143.86 (-3.60%)
MSFT   257.65 (-3.44%)
FB   196.29 (-3.12%)
GOOGL   2,267.82 (-2.65%)
AMZN   2,183.95 (-5.35%)
TSLA   736.32 (-3.32%)
NVDA   174.64 (-3.92%)
BABA   89.50 (-2.71%)
NIO   16.19 (-2.65%)
AMD   99.79 (-2.62%)
CGC   5.75 (-2.38%)
MU   72.37 (-2.83%)
T   20.42 (-0.73%)
GE   75.56 (-1.10%)
F   13.04 (-3.62%)
DIS   105.58 (-2.82%)
AMC   13.33 (+3.33%)
PFE   50.69 (-1.27%)
PYPL   78.23 (-1.91%)
NFLX   184.06 (-3.41%)
S&P 500   3,978.47 (-2.70%)
DOW   31,899.16 (-2.31%)
QQQ   296.67 (-3.10%)
AAPL   143.86 (-3.60%)
MSFT   257.65 (-3.44%)
FB   196.29 (-3.12%)
GOOGL   2,267.82 (-2.65%)
AMZN   2,183.95 (-5.35%)
TSLA   736.32 (-3.32%)
NVDA   174.64 (-3.92%)
BABA   89.50 (-2.71%)
NIO   16.19 (-2.65%)
AMD   99.79 (-2.62%)
CGC   5.75 (-2.38%)
MU   72.37 (-2.83%)
T   20.42 (-0.73%)
GE   75.56 (-1.10%)
F   13.04 (-3.62%)
DIS   105.58 (-2.82%)
AMC   13.33 (+3.33%)
PFE   50.69 (-1.27%)
PYPL   78.23 (-1.91%)
NFLX   184.06 (-3.41%)
S&P 500   3,978.47 (-2.70%)
DOW   31,899.16 (-2.31%)
QQQ   296.67 (-3.10%)
AAPL   143.86 (-3.60%)
MSFT   257.65 (-3.44%)
FB   196.29 (-3.12%)
GOOGL   2,267.82 (-2.65%)
AMZN   2,183.95 (-5.35%)
TSLA   736.32 (-3.32%)
NVDA   174.64 (-3.92%)
BABA   89.50 (-2.71%)
NIO   16.19 (-2.65%)
AMD   99.79 (-2.62%)
CGC   5.75 (-2.38%)
MU   72.37 (-2.83%)
T   20.42 (-0.73%)
GE   75.56 (-1.10%)
F   13.04 (-3.62%)
DIS   105.58 (-2.82%)
AMC   13.33 (+3.33%)
PFE   50.69 (-1.27%)
PYPL   78.23 (-1.91%)
NFLX   184.06 (-3.41%)
S&P 500   3,978.47 (-2.70%)
DOW   31,899.16 (-2.31%)
QQQ   296.67 (-3.10%)
AAPL   143.86 (-3.60%)
MSFT   257.65 (-3.44%)
FB   196.29 (-3.12%)
GOOGL   2,267.82 (-2.65%)
AMZN   2,183.95 (-5.35%)
TSLA   736.32 (-3.32%)
NVDA   174.64 (-3.92%)
BABA   89.50 (-2.71%)
NIO   16.19 (-2.65%)
AMD   99.79 (-2.62%)
CGC   5.75 (-2.38%)
MU   72.37 (-2.83%)
T   20.42 (-0.73%)
GE   75.56 (-1.10%)
F   13.04 (-3.62%)
DIS   105.58 (-2.82%)
AMC   13.33 (+3.33%)
PFE   50.69 (-1.27%)
PYPL   78.23 (-1.91%)
NFLX   184.06 (-3.41%)
OTCMKTS:PFSCF

ProMetic Life Sciences (PFSCF) Stock Forecast, Price & News

$5.47
-0.20 (-3.58%)
(As of 11/15/2019)
Add
Compare
Today's Range
$5.47
▼
$5.47
50-Day Range
$5.47
▼
$5.47
52-Week Range
$5.47
▼
$352.00
Volume
200 shs
Average Volume
279 shs
Market Capitalization
$127.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.46
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMetic Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ProMetic Life Sciences logo

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Headlines

May 10, 2022 | markets.businessinsider.com
Here's what to expect from Prometic Life Sciences's earnings report
April 28, 2022 | americanbankingnews.com
ProMetic Life Sciences (OTCMKTS:PFSCF) Shares Cross Below Fifty Day Moving Average of $5.47
May 17, 2021 | markets.businessinsider.com
Stock Alert: Liminal BioSciences Gains 3%
April 14, 2021 | marketwatch.com
Global Kidney Fibrosis Treatment Market Regional Trends & Growth Projections 2026
April 14, 2021 | marketwatch.com
U.S Kidney/Renal Fibrosis Treatment Market Share Analysis Of Key Participants And Their Competitive Landscape up to 2027
April 9, 2021 | marketwatch.com
Scleroderma Therapeutics Market Size to Record US$ 2.10 Bn through 2028 - MarketWatch
February 2, 2021 | marketwatch.com
Liver Diseases Therapeutics Drugs Market Size 2021 by Consumption Volume, Average Price, Revenue, Market Share and Trend to 2025
January 29, 2021 | marketwatch.com
Kidney Fibrosis Treatment Market 2021 Overview and Outlook – Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland)
December 28, 2020 | marketwatch.com
Idiopathic Pulmonary Fibrosis Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
December 16, 2020 | markets.businessinsider.com
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
November 7, 2020 | markets.businessinsider.com
Prometic Life Sciences Inc Registered Shs hosts conference call for investors
September 21, 2020 | finance.yahoo.com
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)
September 17, 2020 | bloomberg.com
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PFSCF
Previous Symbol
NASDAQ:PFSCF
CUSIP
N/A
CIK
N/A
Web
www.prometic.com
Phone
1-450-781-0115
Fax
N/A
Employees
487
Year Founded
N/A

Sales & Book Value

Annual Sales
$36.55 million
Price / Sales
3.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($67.63) per share
Price / Book
-0.08

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-150.73 million
Net Margins
-894.02%
Pretax Margin
N/A
Return on Equity
-3,350.55%
Return on Assets
-67.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.95
Quick Ratio
0.71

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
23,313,000
Free Float
N/A
Market Cap
$127.45 million
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













ProMetic Life Sciences (OTCMKTS:PFSCF) Frequently Asked Questions

Who are ProMetic Life Sciences' key executives?
ProMetic Life Sciences' management team includes the following people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)
What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the OTCMKTS under the ticker symbol "PFSCF."

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProMetic Life Sciences' stock price today?

One share of PFSCF stock can currently be purchased for approximately $5.47.

How much money does ProMetic Life Sciences make?

ProMetic Life Sciences has a market capitalization of $127.45 million and generates $36.55 million in revenue each year.

How many employees does ProMetic Life Sciences have?

ProMetic Life Sciences employs 487 workers across the globe.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is www.prometic.com.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.